Nkarta, Inc.

NKTX Healthcare Biotechnology

In the quarter to June 2026, EPS fell 74.2% and free cash flow fell 29.2%, each against the same quarter a year earlier.

1.80 0.13 −6.74%
Market cap
$138.2M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
7.98 12.96 12.69 15.23
Net Debt/EBITDA
4.47 7.87 9.35 10.89
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.33) (0.39) (0.30) (0.25)
Book value per Share
3.33 3.85 4.22 4.56
Free Cash Flow
(24.41) (28.61) (22.21) (18.68)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates